Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDA NASDAQ:NBTX NASDAQ:SKYE NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.20+1.9%$7.41$5.17▼$9.15$414.07M0.89127,077 shs121,524 shsNBTXNanobiotix$8.55+0.3%$6.89$2.76▼$10.59$409.65M0.4711,784 shs1,697 shsSKYESkye Bioscience$4.02+7.2%$3.73$1.14▼$7.11$124.89M2.34640,692 shs439,025 shsUPXIUpexi$6.00-5.3%$5.97$1.90▼$22.57$351.22M-0.473.77 million shs3.76 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada+1.29%+0.57%+3.07%+3.07%+29.30%NBTXNanobiotix-1.45%-7.79%+23.03%+80.89%+54.63%SKYESkye Bioscience+11.61%+7.76%-1.06%+54.00%-37.40%UPXIUpexi-4.52%-21.76%+20.11%-43.53%+53.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.20+1.9%$7.41$5.17▼$9.15$414.07M0.89127,077 shs121,524 shsNBTXNanobiotix$8.55+0.3%$6.89$2.76▼$10.59$409.65M0.4711,784 shs1,697 shsSKYESkye Bioscience$4.02+7.2%$3.73$1.14▼$7.11$124.89M2.34640,692 shs439,025 shsUPXIUpexi$6.00-5.3%$5.97$1.90▼$22.57$351.22M-0.473.77 million shs3.76 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada+1.29%+0.57%+3.07%+3.07%+29.30%NBTXNanobiotix-1.45%-7.79%+23.03%+80.89%+54.63%SKYESkye Bioscience+11.61%+7.76%-1.06%+54.00%-37.40%UPXIUpexi-4.52%-21.76%+20.11%-43.53%+53.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 2.67Moderate Buy$13.0080.68% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-6.38% DownsideSKYESkye Bioscience 3.14Buy$15.50285.57% UpsideUPXIUpexi 3.50Strong Buy$15.50158.55% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, NBTX, UPXI, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.008/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.006/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$15.006/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$160.95M2.57$0.51 per share14.18$4.51 per share1.60NBTXNanobiotix$39.18M10.46N/AN/A($1.51) per share-5.66SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/AUPXIUpexi$26M13.58N/AN/A$6.24 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$14.46M$0.3421.1822.480.7411.22%7.41%5.18%11/12/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)SKYESkye Bioscience-$26.57M-$1.06N/AN/AN/AN/A-76.03%-69.20%N/AUPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest SKYE, NBTX, UPXI, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KMDAKamada$0.09$0.13+$0.04$0.13$158.59 million$44.75 million8/7/2025Q2 2025SKYESkye Bioscience-$0.34-$0.44-$0.10-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamadaN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A4.002.21NBTXNanobiotixN/A1.041.04SKYESkye BioscienceN/A6.096.09UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%NBTXNanobiotix38.81%SKYESkye Bioscience21.09%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipKMDAKamada36.10%NBTXNanobiotix3.45%SKYESkye Bioscience4.50%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.51 million36.75 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableSKYESkye Bioscience1130.99 million29.59 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableSKYE, NBTX, UPXI, and KMDA HeadlinesRecent News About These CompaniesUpexi to Participate in Upcoming September ConferencesSeptember 3 at 1:21 PM | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3 at 8:20 AM | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comUpexi Invests in Alpha Exchange for Revenue ShareAugust 27, 2025 | tipranks.comUpexi Amends Securities Purchase AgreementAugust 26, 2025 | msn.comUpexi Approves Share Increase and New AgreementAugust 20, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Trading Down 10% - Time to Sell?August 17, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateAugust 17, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Shares Gap Down - Here's What HappenedAugust 16, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor FitzgeraldAugust 16, 2025 | marketbeat.comDigital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4KAugust 15, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comFormer Amazon aggregator turns to Solana, records $70K in daily rewardsAugust 13, 2025 | msn.comUpexi establishes Advisory Committee, welcomes Hayes as first memberAugust 13, 2025 | msn.comUpexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?August 12, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)August 11, 2025 | prnewswire.comUpexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What HappenedAugust 9, 2025 | marketbeat.comCrypto Currents: SEC eases staking rules as bitcoin miners pivot to AIAugust 6, 2025 | msn.comUpexi Surpasses 2 Million SOL in its TreasuryAugust 5, 2025 | taiwannews.com.twTSolana Treasury Company Upexi Surpasses 2M in SOL HoldingsAugust 5, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global PartnersAugust 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, NBTX, UPXI, and KMDA Company DescriptionsKamada NASDAQ:KMDA$7.20 +0.14 (+1.91%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Nanobiotix NASDAQ:NBTX$8.54 +0.03 (+0.29%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Skye Bioscience NASDAQ:SKYE$4.02 +0.27 (+7.20%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Upexi NASDAQ:UPXI$6.00 -0.34 (-5.29%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
